167 related articles for article (PubMed ID: 21256546)
1. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer.
Mountzios I; Bournakis E; Efstathiou E; Varkaris A; Wen S; Chrisofos M; Deliveliotis C; Alamanis C; Anastasiou I; Constantinides C; Karadimou A; Tsiatas M; Papadimitriou C; Bamias A; Dimopoulos MA
Urology; 2011 Mar; 77(3):682-7. PubMed ID: 21256546
[TBL] [Abstract][Full Text] [Related]
2. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
[TBL] [Abstract][Full Text] [Related]
3. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
[TBL] [Abstract][Full Text] [Related]
4. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.
Loriot Y; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Bossi A; Chauchereau A; Fizazi K
Eur J Cancer; 2010 Jul; 46(10):1770-2. PubMed ID: 20483588
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
Schallier D; Decoster L; Braeckman J; Fontaine C; Degrève J
Anticancer Res; 2012 Feb; 32(2):633-41. PubMed ID: 22287756
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
Kibel AS; Rosenbaum E; Kattan MW; Picus J; Dreicer R; Klein EA; Chatta GS; Nelson JB; DiPaola RS; Roth BJ; Cookson MS; Wilding G; Jarrard DF; Beer TM; Ryan CW; Petrylak DP; Benson MC; Partin AW; Garrett-Mayer E; Eisenberger MA
J Urol; 2007 May; 177(5):1777-81. PubMed ID: 17437819
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
Eymard JC; Oudard S; Gravis G; Ferrero JM; Theodore C; Joly F; Priou F; Krakowski I; Zannetti A; Thill L; Beuzeboc P
BJU Int; 2010 Oct; 106(7):974-8. PubMed ID: 20230389
[TBL] [Abstract][Full Text] [Related]
9. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
Beer TM; Ryan CW; Venner PM; Petrylak DP; Chatta GS; Ruether JD; Chi KN; Young J; Henner WD;
Cancer; 2008 Jan; 112(2):326-30. PubMed ID: 17960793
[TBL] [Abstract][Full Text] [Related]
10. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
11. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
13. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.
Sridhar SS; Canil CM; Chi KN; Hotte SJ; Ernst S; Wang L; Chen EX; Juhasz A; Yen Y; Murray P; Zwiebel JA; Moore MJ
Cancer Chemother Pharmacol; 2011 Apr; 67(4):927-33. PubMed ID: 20602233
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.
Dreicer R; Magi-Galluzzi C; Zhou M; Rothaermel J; Reuther A; Ulchaker J; Zippe C; Fergany A; Klein EA
Urology; 2004 Jun; 63(6):1138-42. PubMed ID: 15183967
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
[TBL] [Abstract][Full Text] [Related]
18. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone.
Shimazui T; Kawai K; Miyanaga N; Kojima T; Sekido N; Hinotsu S; Oikawa T; Joraku A; Akaza H
Jpn J Clin Oncol; 2007 Aug; 37(8):603-8. PubMed ID: 17673473
[TBL] [Abstract][Full Text] [Related]
19. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K
Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811
[TBL] [Abstract][Full Text] [Related]
20. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Meluch AA; Spigel DR; Barton J; Simons L; Meng C; Gould B; Greco FA
Clin Genitourin Cancer; 2007 Mar; 5(4):278-83. PubMed ID: 17553208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]